Modak et al. (2022) showed that alternatively activated CD206+ M2a macrophages efficiently cross-present soluble tumor-associated antigens (TAAs), which is a leading tumor antigen-directed cytotoxic CD8+ T cell response and type I IFN signaling mechanism, a key aspect of anti-tumor immunity [32]. The gene discussed is MRC1; the disease is neoplasm.